The association said the new guidance is based on anecdotal reports of patients who take these drugs experiencing regurgitation and aspiration while undergoing anesthesia. There is “a lack of scientific data on how GLP-1 receptor agonists affect patients having surgery and interact with anesthesia,” ASA President Michael Champeau, MD, said in a news release.
GLP-1 drugs, or glucagon-like peptide 1 agonists, are a class of medications that suppress appetite. As of June 29, the FDA has approved 10 GLP-1 therapies:
- Adlyxin (lixisenatide)
- Bydureon BCise (exenatide extended release)
- Byetta (exenatide)
- Mounjaro (tirzepatide)
- Ozempic (semaglutide)
- Rybelsus (semaglutide)
- Saxenda (liraglutide)
- Trulicity (dulaglutide)
- Victoza (liraglutide)
- Wegovy (semaglutide)
All are approved to treat Type 2 diabetes except for Saxenda and Wegovy, which are approved for weight loss.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
